If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
420
results.
Updated on
15/07/2026 [07:52:00]
Results 250 to 275 of 420
Absstract of: WO2024239122A1
Provided herein is a method for diagnosing and treating Alzheimer's disease comprising: (a) providing a biological sample obtained from the subject; (b) measuring concentration levels from the obtained sample, at least one, at least two, at least three, at least four or at least five Alzheimer's-related metabolites described herein and/or at least one, at least two, at least three, at least four or at least five Alzheimer's-related proteins described herein; (c) comparing the concentration levels of the Alzheimer's-related metabolites and/or proteins from the obtained sample to the concentration levels of corresponding reference Alzheimer's-related metabolites and/or proteins from an Alzheimer's- negative sample; (d) identifying the subject as having Alzheimer's if the concentration levels of the Alzheimer's-related metabolites and/or proteins from the obtained sample are different relative to the concentration levels of the reference Alzheimer's-related metabolites and/or proteins from the Alzheimer's-negative sample; and (e) treating or causing treatment of the subject.
Absstract of: US20260153437A1
The invention relates to a multispectral plasmonic sensor for chiral molecular barcoding, employing a pixelated array of nanostructured plasmonic units coupled with a photonic cavity. Each pixel is tuned to resonate at distinct mid-infrared (mid-IR) wavelengths, facilitating simultaneous detection of molecular chiral and vibrational properties. The system generates near-perfect resonant absorption, maximizing electric and magnetic field enhancements. When illuminated with circularly polarized light, the sensor produces a chiral near-field with handedness determined by the polarization direction. The interaction between the sensor and chiral molecules is quantified using dissymmetry factors, forming unique chiral barcodes that encode molecular behavior across multiple wavelengths. The sensor enables surface-enhanced infrared absorption (SEIRA) induced surface-enhanced vibrational circular dichroism (SEVCD) measurements, providing comprehensive chiral and vibrational analysis. This approach creates a unique barcode for every chiral active molecule, supporting advanced applications in chemical analysis and molecular identification.
Absstract of: US20260155261A1
Disclosed are non-pharmaceutical compositions, kits, systems, and methods configured to support immunological fitness and continuous cellular defenses. In certain embodiments, a kit includes a bioavailability-optimized ingestible powder and a bioavailability-optimized ingestible liquid provided together with guidance associating coordinated use of the compositions with activation of one or more biological defense pathways. Additional embodiments include preparedness kits comprising interim vitamin D dosing components and guidance materials suitable for deployment prior to individualized testing. System embodiments may integrate distribution mechanisms, data association components, processing components, and optional environmental sensing to support population-scale risk mitigation. Methods are disclosed for supporting immunological fitness, maintaining biological barriers, and associating measurable biological and environmental metrics with population-level risk assessment and actuarial applications, without requiring pharmaceutical intervention.
Absstract of: WO2026117508A1
The present disclosure provides methods of predicting/diagnosing immunotherapeutic toxicity in a subject using levels of at least one biomarker protein in a biological sample from the subject, wherein the at least one biomarker protein comprises C4orf47, CXCL1, LMNTD2, ERVV-1, PSRC1, SPRED2, KIF22, MRRF, DAAM1, ABO, MAP9, or any combination thereof. Also provided herein are methods of determining therapeutic regimens for patients based on the biomarker levels.
Absstract of: WO2026115269A1
The present invention provides a method for detecting an analyte in a sample, the method comprising steps (i)-(iv). Thus, the present invention provides a method for detecting an analyte in a sample in which only the reporter reagents in the vicinity of the surface of the substrate results in a signal, the signal being a local region having an absence of the optical component. It is the set of local regions of the optical component having an absence of the optical component that are detected.
Absstract of: EP4752550A2
0001 Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
Absstract of: EP4752155A1
The present invention relates to genetically encoded cellular iron biosensors, in particular to nucleic acids encoding the same, vectors and cells comprising the nucleic acid(s), in vitro methods for measuring, and optionally monitoring, cellular Fe2+ and/or cellular iron-sulfur cluster (ISC), in vitro screening methods for a compound that affects cellular Fe2+ and/or cellular ISC, and to in vitro methods for identifying a dosage and/or formulation of a compound that affects cellular Fe2+ and/or cellular ISC.
Absstract of: WO2025024817A1
Embodiments of the instant disclosure relate to diagnosis and/or early diagnosis, intervention and/or treatment of Alzheimer's disease (AD). Certain embodiments relate to methods for identifying and isolating/analyzing an enriched population of neuronal, microglial and/or astrocytic exosomes from a sample of a subject and detecting biomarkers of interest on one or more exosomes in the enriched population to diagnose a neurodegenerative condition, Alzheimer's disease (AD), an AD-related dementia/condition, Down Syndrome (DS) or the like at an earlier stage than afforded by current therapies using minimally invasive technologies at reduced costs in time and expenses. Other embodiments relate to assessing interventions and evaluating treatment regimens for neurodegenerative disorders using approaches disclosed herein.
Absstract of: EP4752856A1
0001 The present invention relates to the field of medical diagnosis, and more particularly to methods for detecting the risk of having mental health-related diseases by means of analyzing morphological changes in specific immune cells of the central nervous system, such as microglia, using convolutional neural network-based artificial intelligence.
Absstract of: CN122130960A
本申请涉及医疗器械领域，具体涉及应用于脑神经科学领域和临床医学领域，涉及诊断或辅助诊断阿尔茨海默病的标志物组合，特别涉及Aβ1‑42、Aβ1‑40和p‑Tau217的组合，尤其是经由Aβ1‑42、Aβ1‑40和p‑Tau217获得的比值p‑Tau217/(Aβ1‑42/Aβ1‑40)。比值p‑Tau217/(Aβ1‑42/Aβ1‑40)受样本保存条件的影响小，更稳定，有助于排除样本保存过程中抗原，例如Aβ1‑42、Aβ1‑40、p‑Tau217不稳定对疾病诊断的影响。
Absstract of: CN122130951A
本发明涉及一种p‑Tau262检测试剂盒及其应用，尤其适用于对早期阿尔茨海默病的精准诊断，本发明p‑Tau262检测试剂盒包括：第一抗体：第一抗体为p‑Tau262特异性抗体；检测试剂：检测试剂包括第二抗体或特异性识别外泌体膜结构的脂质探针，其中，第二抗体与第一抗体识别不同的p‑Tau262抗原表位。本发明通过采用识别不同表位的p‑Tau262特异性抗体组合或搭配外泌体膜探针，不仅实现了对靶标的高灵敏度、高通量检测，解决了现有血液标志物在共病人群中特异性不足的行业痛点。
Absstract of: CN122130941A
本发明涉及一种基于卟啉共价有机框架@聚吲哚五甲醛的光阳极材料及其制备方法和应用，属于光电化学生物传感器技术领域。本发明采用Dha与Tph通过溶剂热法合成D‑T‑COF，并将其修饰于FTO导电基底表面；进一步通过电聚合法沉积P5FIn，在D‑T‑COF表面形成均匀且广域分布的p‑n异质结结构。基于D‑T‑COF@P5FIn复合材料与p‑tau217捕获抗体，构建了可精准识别人血浆中痕量p‑tau217的光电化学免疫传感器阵列，其在灵敏度、特异性和实用性方面均实现显著突破，尤其适用于复杂生物基质中极低浓度标志物的可靠检测，在临床转化应用中展现出广阔前景。
Absstract of: CN122130945A
0001 本发明涉及一种外周血中性粒细胞分子分型试剂盒及其在肺癌早诊的应用，属于肿瘤技术领域。本发明试剂盒包括靶序列的杂交探针和荧光报告探针；所述靶序列杂交探针的核苷酸序列如SEQ ID NO：11‑25所示；所述荧光报告探针核苷酸序列如SEQ ID NO：26所示。本发明将靶序列的杂交探针的序列设计成一部分与靶基因杂交，另一部分与荧光报告探针杂交，通过荧光报告探针的荧光值可以鉴定或区分靶细胞。通过本发明试剂盒可将中性粒细胞鉴定或划分为CXCL8、LYZ、IL1R2、S100A12、IFI16基因阳性表达的中性粒细胞亚群。这些基因阳性表达的中性粒细胞亚群可以用于诊断早期癌症。
Absstract of: CN122127439A
本发明涉及一种新型载脂蛋白E突变截短体及其校准品、质控品的制备方法。载脂蛋白E突变截短体，其氨基酸序列如SEQ ID所示；载脂蛋白E突变截短体检测的校准品、质控品稀释液包括防腐剂、蛋白保护组合物、表面活性剂组合物、离子稳定剂组合物、缓冲液；载脂蛋白E突变体的制备方法，包括如下几点：1，确定突变截短体的具体序列；2，确定突变位点位于野生型载脂蛋白E的78位点；3，含NdeI位点及突变序列；锁定突变；结合大肠杆菌对载脂蛋白E核苷酸进行人工优化；4，通过电泳截取相应的突变的截短体；5，经过大肠杆菌重组，得到载脂蛋白E突变截短体。本发明解决了检测结果与实际临床不符以及载脂蛋白E校准品稳定性差等问题。
Absstract of: WO2024211475A1
Disclosed herein are methods that aid in the determination of whether a subject has or may have sustained an acquired brain injury, such as a traumatic brain injury (TBI), by detecting levels of at least one biomarker, glial fibrillary acidic protein (GFAP), in one or more samples taken from a subject, such as a human subject.
Absstract of: CN122124828A
0001 本发明公开了一种Ti<3>C<2>@MnO<2>异质结构材料及制备方法和应用，本发明以Ti<3>AlC<2>、LiF和HCl为前驱体，通过弱酸刻蚀法将前驱体Ti<3>AlC<2>中的Al原子剥离制备了Ti<3>C<2>，并以Ti<3>C<2>为基质，以高锰酸钾为锰源，采用微波法制备了Ti<3>C<2>@MnO<2>异质结构材料，制备的Ti<3>C<2>@MnO<2>异质结构材料具有催化性能好、电子传输能力强和物化性能稳定的特征。本发明还基于Ti<3>C<2>@MnO<2>异质结构材料具有类氧化酶活性和光电催化活性的性能，构建了比色和光电传感器用于GSH的检测，具有优良的抗干扰能力和高选择性的优点。该传感器具有双重信号的测定功能，可以增加测量的动态范围，并为环境和浓度因素提供内置校正，解决了传感器背景信号干扰大、灵敏度低的问题。
Absstract of: WO2022020388A1
Described herein are methods for assessing likelihood of response of subjects to activatable therapeutic agents and compositions, kits, and methods of preparing and using activatable therapeutic agents. Also described herein are methods for assessing likelihood of response of subjects to activatable therapeutic agents. In some cases, the activatable therapeutic agents of the compositions, kits, and methods disclosed herein can comprise a mammalian protein-derived sequence.
Absstract of: WO2025056488A1
A method for determining a subject's analyte level is disclosed. The method comprises the steps of: • a) non-invasively detecting a first amount of at least one first volatile organic marker originating from a first source of the subject; • b) non-invasively detecting a second amount of at least the first volatile organic marker originating from a second source of the subject, wherein the second source is different from the first source; and • c) determining the subject's analyte level based on the first amount and on the second amount.
Absstract of: WO2024223741A1
Disclosed herein is a method for screening a biological fluid sample for an analyte associated with proteinopathy which relies on a signal that is quadratically proportional to a mass difference generated by molecular interactions of a plurality of first molecular recognition elements (10) and a plurality of second molecular recognition elements.
Absstract of: MX2026005100A
The present invention provides a method for determining a biological age, mortality risk and/or probability of a healthy lifespan of a dog; said method comprising: a) determining a biological age, mortality risk and/or probability of a healthy lifespan of the dog using the level of one or more biomarker(s) in one or more samples obtained from the dog, wherein the one or more biomarker(s) is selected from white blood cell count, serum albumin, serum alkaline phosphatase, serum creatine kinase, haemoglobin, haematocrit, mean corpuscular haemoglobin, serum glucose, mean red cell volume, serum globulin, serum calcium, platelet count, and/or red blood cell count; and b) determining a biological age, mortality risk and/or probability of a healthy lifespan for the dog using a DNA methylation profile from the dog.
Absstract of: WO2024263939A1
The present disclosure relates method of identifying a compound targeting a first protein and a second protein, wherein the first protein and/or the second protein are associated with a disease or disorder.
Absstract of: WO2024226596A1
Systems, devices, and techniques are configured to leverage acoustic-based microfluidic amplification for the detection of a biological substance, such as misfolded proteins associated with a protein-misfolding disease. In one example, a system (100) includes a housing defining a main channel (104) configured to contain a fluid solution containing a sample including a plurality of proteins and one or more side channels (106) in fluid communication with the main channel, wherein each side channel of the one or more side channels are configured to establish a liquid-gas interface (108) between the fluid solution in the main channel and air contained in the one or more side channels. The systems may also include at least one acoustic generation element configured to generate acoustic waves within the air of the one or more side channels that causes vibration of the liquid-gas interface and mixing of the fluid solution within the main channel.
Absstract of: WO2022243435A1
The present invention relates to i) KL1333 for use in the treatment of mitochondrial diseases or diseases associated with mitochodrial diseases such as fatigue such as fatigue syndrome and fatigue associated with a disease or muscle weakness associated with a mitochondrial disease, ii) KL1333 for use in a dosage regime for the treatment of one or more of fatigue, muscle weakness or a mitochondrial disease, iii) use of blood lactate (mM)Zpyruvate (mM) ratio as biomarker of KL1333 treatment effect, wherein a decrease in ratio indicates that the treatment is effective, and iv) use of serum niacinamide and/or xanthine as biomarker of KL1333 treatment effect, wherein an increase in the ratio of niacinamide and/or xanthine concentrations indicates that the treatment is effective and the ratio of niacinamide and/or xanthine concentrations is (serum concentration at test day)/(serum concentration at the start of the treatment).
Absstract of: EP4242304A2
The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins.
Nº publicación: JP2026517839A 02/06/2026
Applicant:
大塚製薬株式会社
Absstract of: WO2024231251A1
The present invention relates to antibodies or antigen-binding fragments thereof with binding specificity for interleukin-1 receptor accessory protein (IL1RAP). Furthermore, it relates to a polynucleotide encoding said antibodies, a vector comprising said polynucleotide and a recombinant host cell comprising said polynucleotide or said vector. Further, it relates to a method for producing said antibodies or antigen-binding fragments. Further, it relates to a composition comprising said antibodies or antigen-binding fragments, said polynucleotide, said vector and/or said host cell. Further, it relates to said antibodies or antigen-binding fragments, said polynucleotide, said vector, said host cell and/or said composition for use in medicine and/or for use in the prevention and/or treatment and/or alleviation and/or detection and/or diagnosis of a disease or disorder susceptible to treatment with an inhibitor of IL-1α, IL-1β, IL-33, IL-36α, IL-36β and/or IL- 36γ signaling, optionally wherein the disease or disorder is associated with cells expressing IL1RAP.
BOPI
Electronic site
